Upadacitinib Tied to Durable RA Response, With Louis Bessette, MD, MScByLouis Bessette, MD, MScNovember 18th 2026Pooled UPHOLD and CLOSE-UP data from 2111 patients show 63.1% remained on upadacitinib at 24 months, with no new safety signals.